Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent

References

• Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2021 [Internet]. Centers for Disease Control and Prevention. [cited 2021 May 2]. Available from: https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html
   Google Scholar
• McCullough KP, Morgenstern H, Saran R, et al. Projecting ESRD Incidence and Prevalence in the United States through 2030. JASN 2019;30(1):127–135.
   Web of Science ®Google Scholar
• Weiss JN, Qu Z, Shivkumar K Electrophysiology of Hypokalemia and Hyperkalemia. Circ Arrhythm Electrophysiol [Internet]. 2017 [cited 2021 May 2];10. Available from: https://www.ahajournals.org/doi/10.1161/CIRCEP.116.004667
   Google Scholar
• Levis J. ECG Diagnosis: hyperkalemia. permj 2013;17(1):69.
   PubMedGoogle Scholar
• Beccari M, Meaney C. Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review. CE 2017;12:11–24.
   Web of Science ®Google Scholar
• Georgianos PI, Revisiting AR. RAAS blockade in CKD with newer potassium-binding drugs. Kidney Int. 2018;93(2):325–334.
   PubMed Web of Science ®Google Scholar
• McCullough P, Costanzo M, Silver M, et al. Novel Agents for the Prevention and Management of Hyperkalemia. Rev Cardiovasc Med. 2015;16(2):140–155.
   PubMed Web of Science ®Google Scholar
• Palmer BF. Potassium Binders for Hyperkalemia in Chronic Kidney Disease—Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis. Mayo Clin Proc. 2020;95(2):339–354.
   PubMed Web of Science ®Google Scholar
• Ryuge A, Nomura A, Shimizu H, et al. Warning: the ECG May Be Normal in Severe Hyperkalemia. Intern Med. 2017;56(16):2243–2244.
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Tortorici AR, Chen JLT, et al. Dietary Restrictions in Dialysis Patients: is There Anything Left to Eat? Semin Dial. 2015;28(2):159–168.
   PubMed Web of Science ®Google Scholar
• Collins AJ, Pitt B, Reaven N, et al. Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes. Am J Nephrol. 2017;46(3):213–221.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen P, Chen J, et al. Association of Low Serum Potassium Levels and Risk for All-Cause Mortality in Patients With Chronic Kidney Disease: a Systematic Review and Meta-Analysis: hypokalemia and Mortality in CKD. Ther Apher Dial. 2019;23(1):22–31.
   PubMed Web of Science ®Google Scholar
• Cupisti A, Kovesdy C, D’Alessandro C, et al. Dietary Approach to Recurrent or Chronic Hyperkalaemia in Patients with Decreased Kidney Function. Nutrients 2018;10(3):261.
   Web of Science ®Google Scholar
• Kelly TN, Raj D, Rahman M, et al. The role of renin–angiotensin–aldosterone system genes in the progression of chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. Nephrol Dial Transplant. 2015;30(10):1711–1718.
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Perico N, Macia M, et al. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int. 2005;68:S57–S65.
   Web of Science ®Google Scholar
• Oh YJ, Kim SM, Shin BC, et al. The Impact of Renin-Angiotensin System Blockade on Renal Outcomes and Mortality in Pre-Dialysis Patients with Advanced Chronic Kidney Disease. PLoS One. 2017;12(1):e0170874. Shimosawa T, editor.
   PubMed Web of Science ®Google Scholar
• Dépret F, Peacock WF, Liu KD, et al. Management of hyperkalemia in the acutely ill patient. Ann Intensive Care. 2019;9(1):32.
   PubMed Web of Science ®Google Scholar
• Abuelo JG. Treatment of Severe Hyperkalemia: confronting 4 Fallacies. Kidney Int Rep. 2018;3(1):47–55.
   PubMed Web of Science ®Google Scholar
• Kim G-H. Pharmacologic Treatment of Chronic Hyperkalemia in Patients with Chronic Kidney Disease. Electrolyte Blood Press. 2019;17(1):1.
   PubMedGoogle Scholar
• US National Library of Medicine. SODIUM POLYSTYRENE SULFONATE Suspension [Internet]. DailyMed. 2020 [cited 2021 May 2]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d48dcf-07bd-4b06-bd6c-7543f1be8357
   Google Scholar
• US Food and Drug Administration. Kayexalate SODIUM POLYSTYRENE SULFONATE, USP Cation-Exchange Resin [Internet]. US Food and Drug Administration. 2010 [cited 2021 May 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/011287s023lbl.pdf
   Google Scholar
• Flinn RB, Merrill JP, Welzant WR. Treatment of the Oliguric Patient with a New Sodium-Exchange Resin and Sorbitol: a Preliminary Report. N Engl J Med. 1961;264(3):111–115.
   PubMed Web of Science ®Google Scholar
• Scherr L, Ogden DA, Mead AW, et al. Management of Hyperkalemia with a Cation-Exchange Resin. N Engl J Med. 1961;264(3):115–119.
   PubMed Web of Science ®Google Scholar
• Chaitman M, Dixit D, Bridgeman MB. Potassium-Binding Agents for the Clinical Management of Hyperkalemia. P T. 2016;41(1):43–50.
   PubMedGoogle Scholar
• Fordjour KN, Walton T, Doran JJ. Management of Hyperkalemia in Hospitalized Patients. Am J Med Sci. 2014;347(2):93–100.
   PubMed Web of Science ®Google Scholar
• Kessler C, Ng J, Valdez K, et al. The use of sodium polystyrene sulfonate in the inpatient management of hyperkalemia. J Hosp Med. 2011;6(3):136–140.
   PubMed Web of Science ®Google Scholar
• Gardiner GW. Kayexalate (Sodium Polystyrene Sulphonate) in Sorbitol Associated with Intestinal Necrosis in Uremic Patients. Canad J Gastroenterol. 1997;11(7):573–577.
   PubMed Web of Science ®Google Scholar
• Chernin G, Gal-Oz A, Ben-Assa E, et al. Secondary Prevention of Hyperkalemia With Sodium Polystyrene Sulfonate in Cardiac and Kidney Patients on Renin-Angiotensin-Aldosterone System Inhibition Therapy. Clin Cardiol. 2012;35(1):32–36.
   PubMed Web of Science ®Google Scholar
• Lepage L, Dufour A-C, Doiron J, et al. Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD. CJASN 2015;10(12):2136–2142.
   PubMed Web of Science ®Google Scholar
• Nasir K, Ahmad A. Treatment of hyperkalemia in patients with chronic kidney disease: a comparison of calcium polystyrene sulphonate and sodium polystyrene sulphonate. J Ayub Med Coll Abbottabad. 2014;26(4):455–458.
   PubMedGoogle Scholar
• Emmett M, Hootkins RE, Fine KD, et al. Effect of three laxatives and a cation exchange resin on fecal sodium and potassium excretion. Gastroenterology 1995;108(3):752–760.
   PubMed Web of Science ®Google Scholar
• Gruy-Kapral C, Emmett M, Santa Ana CA, et al. Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease. JASN 1998;9(10):1924–1930.
   Web of Science ®Google Scholar
• US Food and Drug Administration. Prescribing Information for Patriomer Calcium [Internet]. US Food and Drug Administration. 2015 [cited 2021 May 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205739s000lbl.pdf
   Google Scholar
• Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors. N Engl J Med. 2015;372(3):211–221.
   PubMed Web of Science ®Google Scholar
• Bhattarai S, Pupillo S, Man Singh Dangol G, et al. Patiromer Acetate Induced Hypercalcemia: an Unreported Adverse Effect. Case Rep Nephrol. 2019;2019:1–4.
   Google Scholar
• Wiederkehr MR, Mehta AN, Emmett M. Case report: patiromer-induced hypercalcemia. CNCS 2019;7(1):51–53.
   Google Scholar
• Weir MR, Bakris GL, Gross C, et al. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney Int. 2016;90(3):696–704.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Pitt B, Weir MR, et al. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: the AMETHYST-DN Randomized Clinical Trial. JAMA 2015;314(2):151.
   PubMed Web of Science ®Google Scholar
• Pitt B, Bushinsky D, Garza D, et al. 1-year safety and efficacy of patiromer for hyperkalemia in heart failure patients with chronic kidney disease on renin-angiotensin-aldosterone system inhibitors. J Am Coll Cardiol. 2015;65(10):A855.
   Web of Science ®Google Scholar
• Lesko LJ, Offman E, Brew CT, et al. Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers. J Cardiovasc Pharmacol Ther. 2017;22(5):434–446.
   PubMed Web of Science ®Google Scholar
• Pitt B, Bakris GL, Bushinsky DA, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015;17(10):1057–1065.
   PubMed Web of Science ®Google Scholar
• Bem DS, Sherman JD, Ash SR, et al. Ammonium removal with a novel zirconium silicate. ASAIO J. 2001;47(2):151.
   Google Scholar
• Stavros F, Yang A, Leon A, et al. Characterization of Structure and Function of ZS-9, a K+ Selective Ion Trap. PLoS One. 2014;9(12):e114686. Bansal V, editor.
   PubMed Web of Science ®Google Scholar
• Lee DBN, Roberts M, Bluchel CG, et al. Zirconium: biomedical and Nephrological Applications. ASAIO J. 2010;56(6):550–556.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Sodium Zirconium Cyclosilicate: a Review in Hyperkalaemia. Drugs 2018;78(15):1605–1613.
   PubMed Web of Science ®Google Scholar
• Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients With Hyperkalemia: the HARMONIZE Randomized Clinical Trial. JAMA 2014;312(21):2223.
   PubMed Web of Science ®Google Scholar
• Levien TL, Baker DE. Sodium Zirconium Cyclosilicate. Hosp Pharm. 2019;54(1):12–19.
   PubMed Web of Science ®Google Scholar
• Ash SR, Singh B, Lavin PT, et al. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int. 2015;88(2):404–411.
   PubMed Web of Science ®Google Scholar
• Anker SD, Kosiborod M, Zannad F, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail. 2015;17(10):1050–1056.
   PubMed Web of Science ®Google Scholar
• Roger SD, Spinowitz BS, Lerma EV, et al. Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: an 11-Month Open-Label Extension of HARMONIZE. Am J Nephrol. 2019;50(6):473–480.
   PubMed Web of Science ®Google Scholar
• Packham DK, Rasmussen HS, Lavin PT, et al. Sodium Zirconium Cyclosilicate in Hyperkalemia. N Engl J Med. 2015;372(3):222–231.
   PubMed Web of Science ®Google Scholar
• Fishbane S, Ford M, Fukagawa M, et al. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia. JASN 2019;30(9):1723–1733.
   Web of Science ®Google Scholar
• Spinowitz BS, Fishbane S, Pergola PE, et al. Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: a 12-Month Phase 3 Study. CJASN 2019;14(6):798–809.
   PubMed Web of Science ®Google Scholar
• Nobakht N, Kamgar M, Rastogi A, et al. Limitations of angiotensin inhibition. Nat Rev Nephrol. 2011;7(6):356–359.
   PubMed Web of Science ®Google Scholar
• Rastogi A, Arman F, Alipourfetrati S. New Agents in Treatment of Hyperkalemia: an Opportunity to Optimize Use of RAAS Inhibitors for Blood Pressure Control and Organ Protection in Patients with Chronic Kidney Disease. Curr Hypertens Rep. 2016;18(7):55.
   PubMed Web of Science ®Google Scholar
• Sarwar CMS, Papadimitriou L, Pitt B, et al. Hyperkalemia in Heart Failure. J Am Coll Cardiol. 2016;68(14):1575–1589.
   PubMed Web of Science ®Google Scholar
• Karaboyas A, Zee J, Brunelli SM, et al. Dialysate Potassium, Serum Potassium, Mortality, and Arrhythmia Events in Hemodialysis: results From the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Diseases. 2017;69(2):266–277.
   PubMed Web of Science ®Google Scholar